LEWISVILLE, Texas--(BUSINESS WIRE)--

德克萨斯州路易斯维尔--（商业新闻）--

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Julie Dewey as Chief Investor Relations and Communications Officer. Additionally, as previously announced, Max Reinhardt begins as President of the company’s global spine business.

全球领先的脊柱和骨科公司Orthofix Medical Inc.（纳斯达克：OFIX）今天宣布任命朱莉·杜威（Julie Dewey）为首席投资者关系和沟通官。此外，正如之前宣布的那样，马克斯·莱因哈特开始担任公司全球脊柱业务总裁。

Dewey and Reinhardt will serve on Orthofix’s Executive Leadership Team..

杜威和莱因哈特将加入Orthofix的执行领导团队。。

Julie Dewey, Chief Investor Relations and Communications Officer, Orthofix Medical Inc. (Photo: Business Wire)

Orthofix Medical Inc.首席投资者关系和沟通官朱莉·杜威（Julie Dewey）（照片：商业新闻）

A seasoned investor relations and communications executive, Dewey previously held roles as a corporate officer for multiple global publicly traded medical device companies. Most recently, she served as Chief Communications and Investor Relations Officer for Treace Medical Concepts, Inc., a medical technology company focused on the surgical management of bunion and related midfoot deformities.

杜威（Dewey）是一位经验丰富的投资者关系和沟通主管，此前曾担任多家全球上市医疗器械公司的公司高管。最近，她担任Treace Medical Concepts，Inc.的首席沟通和投资者关系官，Treace Medical Concepts，Inc.是一家医疗技术公司，专注于bunion和相关中足畸形的外科治疗。

Earlier in her career, she was the Senior Vice President and Chief Communications Officer at Wright Medical Group, a global medical device company focused on extremities and biologics that was acquired by Stryker in 2020..

在她的职业生涯早期，她曾担任莱特医疗集团（Wright Medical Group）的高级副总裁兼首席通信官，这是一家专注于四肢和生物制品的全球医疗器械公司，于2020年被史崔克收购。。

“We are excited to welcome Julie to the company,” said Orthofix President and Chief Executive Officer Massimo Calafiore. “She is deeply respected within the industry and brings with her vast knowledge of our markets, technologies, and growth strategies. Her appointment not only strengthens our executive leadership team, but it also further establishes our focus on expanding our outreach with investors and analysts as we continue to drive profitability and growth for our shareholders.”.

Orthofix总裁兼首席执行官马西莫·卡拉菲奥（MassimoCalafiore）表示：“我们很高兴欢迎朱莉加入公司。”。“她在业界备受尊敬，对我们的市场、技术和增长战略有着丰富的了解。她的任命不仅加强了我们的高管领导团队，而且进一步确立了我们在继续推动股东盈利和增长的同时，扩大与投资者和分析师的联系。”。

Dewey is known for her strong focus on transformative IR program development, successfully positioning medical technology companies in the financial market, and expanding outreach and engagement with the investment community.

杜威以其对变革性IR项目开发的强烈关注而闻名，她成功地将医疗技术公司定位于金融市场，并扩大了与投资界的联系和接触。

“I am thrilled to join Orthofix in this new leadership role at such a transformational time in its growth trajectory,” said Dewey. “I look forward to working with Massimo and the rest of the Orthofix team to execute on the company's growth strategy and deliver a best-in-class experience for the investment community and key stakeholders.”.

杜威说：“在Orthofix发展轨迹的转型时期，我很高兴加入Orthofix担任这一新的领导角色。”。“我期待着与Massimo和Orthofix团队的其他成员合作，执行公司的增长战略，为投资界和关键利益相关者提供一流的体验。”。

About Julie Dewey

关于朱莉·杜威

Julie Dewey has more than 25 years of experience in investor relations, corporate communications and marketing leadership roles at several medical technology companies. Dewey served as Chief Communications and Investor Relations Officer at Treace Medical Concepts, Inc. Prior to Treace, Dewey was Chief Corporate Communications and IR Officer at Nevro Corp.

朱莉·杜威（Julie Dewey）在多家医疗技术公司的投资者关系、企业传播和营销领导角色方面拥有25年以上的经验。杜威曾担任Treace Medical Concepts，Inc.的首席通信和投资者关系官。在Treace之前，杜威曾担任Nevro Corp.的首席企业通信和IR官。

Before joining Nevro, she was Senior Vice President and Chief Communications Officer at Wright Medical Group, N.V., a leading orthopaedic company focused on extremities and biologics that was acquired by Stryker in 2020. Earlier in her career, Dewey held investor relations and marketing positions at top medical technology companies including ev3 Inc.

在加入Nevro之前，她是新泽西州Wright Medical Group的高级副总裁兼首席沟通官，Wright Medical Group是一家领先的骨科公司，专注于四肢和生物制品，于2020年被Stryker收购。在她的职业生涯早期，杜威曾在包括ev3 Inc.在内的顶级医疗技术公司担任投资者关系和营销职位。

(acquired by Covidien), Kyphon Inc. (acquired by Medtronic) and Thoratec Corporation (acquired by St. Jude Medical/Abbott)..

（被Covidien收购）、Kyphon Inc.（被Medtronic收购）和Thoratec Corporation（被St.Jude Medical/Abbott收购）。。

Dewey holds a BS in Business Administration from the University of Southern California and a Master of Business Administration degree from Pepperdine University. Dewey is a Fellow of the National Investor Relations Institute (NIRI), the professional association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents.

杜威拥有南加州大学工商管理学士学位和佩珀丁大学工商管理硕士学位。杜威是美国国家投资者关系研究所（NIRI）的研究员，该研究所是由公司高管和投资者关系顾问组成的专业协会，负责公司管理层、股东、证券分析师和其他金融界成员之间的沟通。

Dewey also holds the Investor Relations Charter (IRC) credential..

杜威还持有投资者关系宪章（IRC）证书。。

As an inducement to enter into employment with Orthofix, Dewey was granted (i) performance-based vesting restricted stock units that settle into 61,444 shares of common stock at target achievement, (ii) time-based vesting restricted stock units that settle into 30,722 shares of common stock, and (iii) stock options to purchase 70,620 shares of common stock.

作为与Orthofix就业的诱因，杜威被授予（i）以业绩为基础的授予限制性股票单位，在目标实现时结算为61444股普通股，（ii）以时间为基础的授予限制性股票单位，结算为30722股普通股，以及（iii）购买70620股普通股的股票期权。

The performance-based vesting restricted stock units vest at the end of a three-year performance period based on the Company’s total stockholder return relative to an industry peer group index during such period, while the time-based vesting restricted stock units vest in equal tranches over three years.

基于业绩的行权限制性股票单位在三年业绩期结束时根据公司在此期间相对于行业同行集团指数的总股东回报授予，而基于时间的行权限制性股票单位在三年内等额授予。

The stock options vest upon achievement of both service- and performance-based criteria, whichever is the later of (a) the date certain service-based conditions are met (which will be met over three years) and (b) the date that the average closing price of the Company’s common stock over a one-month calendar period has been equal to or great than 150% of the closing price of the Company’s common stock on the grant date.

股票期权在达到基于服务和绩效的标准后授予，以（a）满足某些基于服务的条件的日期（将在三年内满足）和（b）公司普通股在一个月日历期间的平均收盘价等于或大于授予日公司普通股收盘价的150%的日期中较晚者为准。

The grants, which were approved by Orthofix’s Board of Directors, were made under standalone inducement award agreements approved pursuant to NASDAQ Marketplace Rule 5635(c)(4)..

这些赠款由Orthofix董事会批准，是根据纳斯达克市场规则5635（c）（4）批准的独立诱导奖励协议进行的。。

Max Reinhardt Starts as President of Global Spine

马克斯·莱因哈特开始担任全球脊柱总裁

Max Reinhardt has stepped into the role of President of Global Spine where he will lead the company’s spine and biologics business.

马克斯·莱因哈特（Max Reinhardt）出任全球脊柱总裁，将领导该公司的脊柱和生物制品业务。

As an inducement to enter into employment with Orthofix, Reinhardt was granted (i) performance-based vesting restricted stock units that settle into 28,802 shares of common stock at target achievement, (ii) time-based vesting restricted stock units that settle into 14,401 shares of common stock, and (iii) stock options to purchase 190,731 shares of common stock.

作为受雇于Orthofix的诱因，Reinhardt被授予（i）以业绩为基础的授予限制性股票单位，在目标实现时结算为28802股普通股，（ii）以时间为基础的授予限制性股票单位，结算为14401股普通股，以及（iii）购买190731股普通股的股票期权。

The performance-based vesting restricted stock units vest at the end of a three-year performance period based on the Company’s total stockholder return relative to an industry peer group index during such period, while the time-based vesting restricted stock units vest in equal tranches over three years.

基于业绩的行权限制性股票单位在三年业绩期结束时根据公司在此期间相对于行业同行集团指数的总股东回报授予，而基于时间的行权限制性股票单位在三年内等额授予。

In regard to the stock options, 33,103 of the stock options vest upon achievement of both service- and performance-based criteria, whichever is the later of (a) the date certain service-based conditions are met (which will be met over three years) and (b) the date that the average closing price of the Company’s common stock over a one-month calendar period has been equal to or great than 150% of the closing price of the Company’s common stock on the grant date.

就股票期权而言，33103份股票期权在达到基于服务和绩效的标准后授予，以（a）满足某些基于服务的条件的日期（将在三年内满足）和（b）公司普通股在一个月日历期间的平均收盘价等于或大于授予日公司普通股收盘价的150%的日期中较晚者为准。

The remaining 157,628 stock options vest on the third anniversary of the grant date. The grants, which were approved by Orthofix’s Board of Directors, were made under standalone inducement award agreements approved pursuant to NASDAQ Marketplace Rule 5635(c)(4)..

剩余的157628份股票期权在授予日期的三周年纪念日授予。这些赠款由Orthofix董事会批准，是根据纳斯达克市场规则5635（c）（4）批准的独立诱导奖励协议进行的。。

About Orthofix

关于Orthofix

Orthofix is a leading global spine and orthopedics company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and a leading surgical navigation system. Its products are distributed in more than 60 countries worldwide.

Orthofix是一家全球领先的脊柱和骨科公司，拥有生物制剂、创新脊柱硬件、骨生长疗法、专业骨科解决方案和领先的外科导航系统的综合投资组合。其产品分布在全球60多个国家。

The Company is headquartered in Lewisville, Texas, where it conducts general business, product development, medical education and manufacturing, and has primary offices in Carlsbad, CA, with a focus on spine and biologics product innovation and surgeon education, and Verona, Italy, with an emphasis on product innovation, production, and medical education for orthopedics.

该公司总部位于德克萨斯州路易斯维尔，从事一般业务、产品开发、医学教育和制造，主要办事处位于加利福尼亚州卡尔斯巴德，专注于脊柱和生物制品产品创新和外科医生教育，以及意大利维罗纳，重点是骨科产品创新、生产和医学教育。

The combined Company’s global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Maidenhead, UK, Munich, Germany, Paris, France and São Paulo, Brazil..

合并后公司的全球研发、商业和制造足迹还包括位于加利福尼亚州欧文、加拿大多伦多、加利福尼亚州桑尼维尔、英国梅登黑德、德国慕尼黑、法国巴黎和巴西圣保罗的设施和办事处。。

Forward-Looking Statements

前瞻性声明

This news release may include forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” “continue” or other comparable terminology.

本新闻稿可能包括经修订的《1934年证券交易法》第21E节和经修订的《1933年证券法》第27A节所指的前瞻性声明。在某些情况下，您可以通过术语来识别前瞻性陈述，例如“可能”、“将”、“应该”、“预期”、“计划”、“预期”、“相信”、“估计”、“项目”、“打算”、“预测”、“潜力”、“继续”或其他类似术语。

Orthofix cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Each forward-looking statement contained in this news release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.

Orthofix提醒您，本新闻稿中不描述历史事实的陈述是基于公司当前预期和假设的前瞻性陈述。本新闻稿中包含的每一项前瞻性声明都存在风险和不确定性，这些风险和不确定性可能导致实际结果与该声明中明示或暗示的结果存在重大差异。

Applicable risks and uncertainties include, among others: the ability of newly launched products to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of robust clinical validation; and the risks identified under the heading “Risk Factors” in Orthofix Medical Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the Securities and Exchange Commission (SEC) on March 5, 2024.

适用的风险和不确定性包括：新推出的产品能够按照设计和预期执行，并满足外科医生和患者的需求，包括由于缺乏强有力的临床验证；以及Orthofix Medical Inc.截至2023年12月31日财年的10-K表年度报告中“风险因素”标题下确定的风险，该报告于2024年3月5日提交给美国证券交易委员会（SEC）。

The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Orthofix does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law..

公司向证券交易委员会提交的公开文件可在www.sec.gov上查阅。请注意不要过度依赖前瞻性声明，这些声明仅在作出之日起生效。Orthofix不打算修改或更新本新闻稿中规定的任何前瞻性声明，以反映本新闻稿日期后发生的事件或情况，法律可能要求的除外。。

Media Relations

媒体关系

Denise Landry

Denise Landry

DeniseLandry@Orthofix.com

DeniseLandry@Orthofix.com

214.937.2529

214.937.2529

Investor Relations

投资者关系

Julie Dewey

朱莉杜威

JulieDewey@Orthofix.com

JulieDewey@Orthofix.com

209.613.6945

209.613.6945

Source: Orthofix Medical Inc.

资料来源：Orthofix Medical Inc。